by Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile duct. The bile duct is the tube that carries bile from the liver to the small intestine. Bile is needed for digestion and helps the body absorb fat. Bile duct cancer is rare, and can form in any part of the bile duct system, including the small ducts inside the liver (intrahepatic bile duct cancer), the long duct outside the liver that connects the liver and small intestine (extrahepatic bile duct cancer), or the place where the gallbladder and bile duct meet (gallbladder/bile duct cancer). Symptoms include jaundice, abdominal pain, itchy skin, weight loss, and fatigue. Diagnosis involves blood tests, imaging tests such as MRI or CT scan, endoscopic ultrasound, and a biopsy. Treatment options depend on the stage of cancer but may involve surgery, chemotherapy, radiation therapy, liver transplantation, or targeted drug therapy.
The global Bile Duct Cancer Market is estimated to be valued at US$ 235.9 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the bile duct cancer market is the introduction of targeted drug therapies. As researchers gain a better understanding of the molecular changes that drive bile duct cancer growth and progression, new targeted therapies are being developed and approved. For example, Incyte Corporation’s Pemigatinib is a selective fibroblast growth factor receptor (FGFR) inhibitor approved for patients with previously treated, advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. Agios Pharmaceuticals’ Ivosidenib is a targeted IDH1 inhibitor approved for patients with previously treated IDH1 mutant cholangiocarcinoma. These targeted therapies offer new treatment options and have shown positive clinical outcomes with manageable safety profiles compared to traditional chemotherapy. Increased R&D efforts focused on precision medicine approaches will continue driving the development of new targeted therapies in coming years.
Porter’s Analysis
Threat of new entrants: The bile duct cancer market has moderate threat as the diagnostics and treatment procedures are complex and require high investments for R&D.
Bargaining power of buyers: The bargaining power is moderate as based on the stages of disease, treatment options vary and patients have options to switch between providers.
Bargaining power of suppliers: The suppliers have moderate to high power as key players are investing heavily in R&D and product pipeline.
Threat of new substitutes: Low threat as bile duct cancer has limited treatment options currently available and new treatment alternatives are emerging slowly.
Competitive rivalry: High as key players are actively involved in clinical trials and product launches to gain higher market share.
Key Takeaways
The Global Bile Duct Cancer Market Size is expected to witness high growth over the forecast period. The global Bile Duct Cancer Market is estimated to be valued at US$ 235.9 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.
North America has the highest prevalence of bile duct cancer and is expected to grow at a CAGR of around 13% during the forecast period. This is attributed to the increasing healthcare spending,rising awareness about early diagnosis, and availablity of advanced treatment options in the region. Asia Pacific region is anticipated to witness fastest growth due to huge patient population, initiatives by governments to increase accessibility to healthcare facilities.
Key players:
Key players operating in the bile duct cancer market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P. and Delcath Systems, Inc. Incyte Corporation focuses on development of novel therapies for cancer treatment. Eisai Co. has a broad pipeline of novel therapeutics for bile duct and other cancers.
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
